(Albany, US) September 28, 2026 – DelveInsight’s “Trigeminal Neuralgia – Pipeline Insight, 2026” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Trigeminal Neuralgia pipeline landscape, covering clinical and nonclinical stage products, therapeutics assessment by product type, stage, route of administration, and molecule type, as well as inactive pipeline products.
Three types of trigeminal neuralgia have been delineated: classical, secondary, and idiopathic, with bilateral trigeminal neuralgia rare and warranting concern about an underlying neurologic or non-neurologic disorder affecting the cranium. Incidence is higher among women than men and increases with age.
Key Takeaways from the Trigeminal Neuralgia Pipeline Report
The Trigeminal Neuralgia pipeline includes 10+ key companies developing therapies, with 10+ products spanning Phase III, Phase II, Phase I, preclinical, and discovery stages, along with discontinued and inactive candidates.
Biogen has the most advanced Trigeminal Neuralgia drug candidate in the pipeline, with Vixotrigine (BIIB074) currently in Phase III development.
Vixotrigine is a centrally and peripherally acting small molecule that functions as a voltage- and use-dependent sodium channel blocker, being developed by Biogen for the treatment of Trigeminal Neuralgia.
Rimegepant, developed by Biohaven Pharmaceuticals, is a calcitonin gene-related peptide (CGRP) receptor antagonist in Phase II development for Trigeminal Neuralgia, with a trial initiated in June 2019.
The pipeline includes therapies across multiple stages of development, highlighting continued innovation in neuropathic pain treatment.
Emerging therapies are being developed through diverse mechanisms, including sodium channel blockers and CGRP receptor antagonists.
Gain Strategic Insights into the Trigeminal Neuralgia Pipeline Landscape
Explore the complete Trigeminal Neuralgia Pipeline Outlook.
Analyze Phase III, Phase II, Phase I, preclinical, and discovery-stage assets.
Evaluate emerging companies and late-stage pipeline therapies.
Understand therapeutic assessment by product type, route of administration, and molecule type.
Track collaborations, licensing, acquisitions, and other pipeline development activities.
Explore detailed pipeline insights and emerging therapies @ Trigeminal Neuralgia Pipeline Insight Report
Trigeminal Neuralgia Disease Overview
Pain can be triggered by routine acts, including brushing teeth, shaving, touching the face, eating or drinking, speaking, or a breeze on the face. Diagnosis is clinical, based on pain restricted to the territory of one or more divisions of the trigeminal nerve and sudden, intense, very short paroxysms.
The anticonvulsant agents carbamazepine and oxcarbazepine have been considered first-choice treatments for control of paroxysmal pain, with gabapentin, pregabalin, and antidepressant agents tried as additional agents. Microvascular decompression is favored as the surgical procedure for cases not responding to medication.
Trigeminal Neuralgia Emerging Drugs Analysis
The Trigeminal Neuralgia pipeline features multiple emerging therapies targeting neuropathic pain through novel mechanisms and differentiated therapeutic approaches.
Phase III Therapy
Vixotrigine (BIIB074): Biogen – A centrally and peripherally acting small molecule voltage- and use-dependent sodium channel blocker. It is currently the most advanced candidate in the Trigeminal Neuralgia pipeline and is being evaluated in Phase III clinical development.
Phase II Therapy
Rimegepant: Biohaven Pharmaceuticals – A calcitonin gene-related peptide (CGRP) receptor antagonist currently being evaluated in Phase II development for Trigeminal Neuralgia, with clinical development initiated in June 2019.
Further product details on additional pipeline candidates are provided in the full report.
Learn More About Emerging Trigeminal Neuralgia Therapies and Clinical Trial Developments @ Trigeminal Neuralgia Clinical Trial Insights
Trigeminal Neuralgia Therapeutic Assessment
The report provides comprehensive therapeutic assessment of Trigeminal Neuralgia drugs across multiple development and product parameters.
Clinical Trial Phases
Late-stage products (Phase III).
Mid-stage products (Phase II).
Early-stage products (Phase I).
Preclinical candidates.
Discovery-stage candidates.
Discontinued and inactive pipeline candidates.
Route of Administration
Intravenous.
Subcutaneous.
Oral.
Intramuscular.
Molecule Type
Monoclonal antibody.
Small molecule.
Peptide.
Product Type
Mono.
Combination.
Mono/Combination.
Trigeminal Neuralgia Pipeline Development Landscape
The Trigeminal Neuralgia pipeline reflects ongoing innovation across clinical and preclinical development, with multiple companies advancing therapies targeting neuropathic pain through differentiated mechanisms of action.
The pipeline spans early discovery through Phase III clinical development and includes both active and inactive candidates, providing insights into the evolving research landscape.
Discover Which Companies and Pipeline Therapies Are Advancing Trigeminal Neuralgia Treatment @ Trigeminal Neuralgia Pipeline Insights
Scope of the Trigeminal Neuralgia Pipeline Report
Geography Covered: Global.
Coverage: 10+ companies and 10+ pipeline drugs across clinical and nonclinical development stages.
Clinical Stages Covered: Phase III, Phase II, Phase I, preclinical, discovery, inactive, and discontinued products.
Therapeutic Assessment: Product type, clinical stage, route of administration, and molecule type.
Additional Coverage: Collaborations, acquisitions and mergers, licensing, designations, and other product-related development activities.
About DelveInsight
DelveInsight is a leading healthcare-focused market research and consulting firm that provides actionable market intelligence and strategic insights across the pharmaceutical, biotechnology, and healthcare industries. With expertise in epidemiology forecasting, competitive intelligence, and pipeline analysis, DelveInsight helps organizations make informed business decisions and stay ahead in an evolving healthcare landscape.
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Mehul MalhotraEmail: Send EmailPhone: 09650213330Address:A-1 NV 89107City: delhiState: IndianaCountry: United StatesWebsite: https://www.delveinsight.com/
